CNRS-University of Strasbourg, Biotechnology and Cell Signalling, Illkirch, France.
Laboratory of Excellence Medalis, Team Neuroimmunology and Peptide Therapy, Institut de Science et d'Ingénierie Supramoléculaire (ISIS), Strasbourg, France.
Nat Rev Drug Discov. 2019 Dec;18(12):923-948. doi: 10.1038/s41573-019-0036-1. Epub 2019 Sep 2.
Lysosomes are membrane-bound organelles with roles in processes involved in degrading and recycling cellular waste, cellular signalling and energy metabolism. Defects in genes encoding lysosomal proteins cause lysosomal storage disorders, in which enzyme replacement therapy has proved successful. Growing evidence also implicates roles for lysosomal dysfunction in more common diseases including inflammatory and autoimmune disorders, neurodegenerative diseases, cancer and metabolic disorders. With a focus on lysosomal dysfunction in autoimmune disorders and neurodegenerative diseases - including lupus, rheumatoid arthritis, multiple sclerosis, Alzheimer disease and Parkinson disease - this Review critically analyses progress and opportunities for therapeutically targeting lysosomal proteins and processes, particularly with small molecules and peptide drugs.
溶酶体是具有参与降解和回收细胞废物、细胞信号转导和能量代谢等过程功能的膜结合细胞器。编码溶酶体蛋白的基因缺陷会导致溶酶体贮积症,其中酶替代疗法已被证明是有效的。越来越多的证据表明,溶酶体功能障碍与更常见的疾病有关,包括炎症和自身免疫性疾病、神经退行性疾病、癌症和代谢性疾病。本文重点分析了自身免疫性疾病和神经退行性疾病(包括狼疮、类风湿性关节炎、多发性硬化症、阿尔茨海默病和帕金森病)中的溶酶体功能障碍,并批判性地分析了针对溶酶体蛋白和过程的治疗靶点,特别是小分子和肽类药物的治疗靶点的进展和机遇。